Celecoxib

Especificaciones

169590-42-5Número CAS

685-962-5Número CE

4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamideNombre IUPAC

C17H14F3N3O2SFórmula química

381.4 g/molPeso molecular

celecoxib; 169590-42-5; Celebrex; Celebra; Onsenal; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; SC-58635; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 184007-95-2; YM 177; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Celecoxibum; DTXSID0022777; SC58635; DFN15; JCX84Q7J1L; 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; NSC-719627; NSC-758624; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide; ELYXYB; DFN-15; CHEBI:41423; benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; DTXCID502777; CONSENSI COMPONENT CELECOXIB; NSC719627; Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-; 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzene-1-sulfonamide; ELYXYB-celecoxib; Celecoxib 50 mg; Celecoxib 100 mg; Celecoxib 200 mg; Celecoxib 400 mg; RefChem:5656; L01XX33; M01AH01; 685-962-5; Celocoxib; Celecox; SC 58635; YM177; MFCD00941298; HSDB 7038; 194044-54-7; Celecoxib (GMP Like); CHEMBL118; 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonami de; Benzenesulfonamide,4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-; Celecoxib [USAN]; NCGC00091455-01; Xilebao; 4-[5-(p-tolyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide; Solexa; Celebrex (TN); SMR000550473; CAS-169590-42-5; SR-01000837528; UNII-JCX84Q7J1L; Celecixib; Celecoxib [USAN:INN:BAN]; CCRIS 9330; Celecoxib?; Celecoxib CRS; TPI-336; Celecoxib (GMP); Onsenal (TN); AI-525; CEP-33222; YM-177; CELEBCOXIB; Celecoxib (Standard); Spectrum_000432; 1oq5; CelecoxibSC 58635; CELECOXIB [INN]; CELECOXIB [JAN]; CELECOXIB [MI]; CELECOXIB [HSDB]; Spectrum2_001576; Spectrum3_001996; Spectrum4_000182; Spectrum5_001324; CELECOXIB [VANDF]; CELECOXIB [MART.]; Epitope ID:613421; CELECOXIB [USP-RS]; CELECOXIB [WHO-DD]; cid_2662; SCHEMBL3708; BSPBio_003596; CELECOXIB [EMA EPAR]; KBioGR_000723; KBioGR_002351; KBioSS_000912; KBioSS_002354; MLS001165684; MLS001195656; MLS001304708; MLS006011862; BIDD:GT0408; DivK1c_000893; SPECTRUM1503678; Celecoxib - Bio-X trade mark; SPBio_001512; Celecoxib (JP18/USP/INN); GTPL2892; orb1310585; CELECOXIB [ORANGE BOOK]; CELECOXIB [EP MONOGRAPH]; BDBM11639; BDBM91683; HMS502M15; KBio1_000893; KBio2_000912; KBio2_002351; KBio2_003480; KBio2_004919; KBio2_006048; KBio2_007487; KBio3_002830; KBio3_003037; CELECOXIB [USP MONOGRAPH]; EX-A175; MSK8005; cMAP_000027; NINDS_000893; GLXC-05108; HMS1922G14; HMS2089L18; HMS2093I07; HMS2234N18; HMS3259L08; HMS3261A14; HMS3373A09; HMS3654H09; HMS3715F11; HMS3867I03; HMS3884M07; HMS5079P03; HY-14398GL; Pharmakon1600-01503678; ALBB-033772; UWA68620; UWA68621; Tox21_111135; Tox21_201964; Tox21_300599; Tox21_500406; US8741944, Comparative Compound; CCG-39354; EBC-06063; HY-14398G; HY-14398R; NSC758624; s1261; STL373576; Celecoxib 1.0 mg/ml in Acetonitrile; 4-[5-(4-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-yl]benzenesulfonamide; AKOS015842517; Tox21_111135_1; AC-4228; CS-0570; DB00482; FC11300; KS-1041; NC00708; NSC 719627; NSC 758624; SB19318; IDI1_000893; NCGC00091455-02; NCGC00091455-03; NCGC00091455-04; NCGC00091455-05; NCGC00091455-06; NCGC00091455-07; NCGC00091455-08; NCGC00091455-09; NCGC00091455-13; NCGC00091455-17; NCGC00254540-01; NCGC00259513-01; NCGC00261091-01; BC164295; BP-30217; HY-14398; NCI60_041049; SY064976; SBI-0051875.P002; UNM-0000305813; CS-0901612; NS00002556; SW199611-3; C07589; D00567; EN300-119504; AB00052396-07; AB00052396-08; AB00052396-09; AB00052396_10; AB00052396_11; Q408801; SR-01000837528-2; SR-01000837528-3; BRD-K02637541-001-02-4; BRD-K02637541-001-06-5; BRD-K02637541-001-17-2; BRD-K02637541-001-18-0; Z1258938406; Celecoxib, European Pharmacopoeia (EP) Reference Standard; Celecoxib, United States Pharmacopeia (USP) Reference Standard; 4-[5-(p-Tolyl)-3-(trifluoromethyl)-1-pyrazolyl]benzenesulfonamide; 4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-Methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide; 5-(4-Methylphenyl)-1-(4-sulfamoylphenyl)-3-(trifluoromethyl)pyrazole; Celecoxib, Pharmaceutical Secondary Standard; Certified Reference Material; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyazol-1-yl]benezenesulfonamideSinónimos